The American Association for Cancer Research will host its annual meeting in Chicago, April 25-30.
Nearly 30 UNC Lineberger and UNC faculty and trainees will be presenting findings, chairing sessions, leading session discussions and sharing their perspectives in topical forums and education sessions during the meeting, which typically attracts more than 20,000 attendees globally.
The meeting’s theme, “Unifying Cancer Science and Medicine: A Continuum of Innovation for Impact,” reflects AACR’s focus on advancing cancer research from the bench to the clinic and back to the bench. More than 7,000 abstracts will be presented in person and digitally.
The UNC presentations include:
Saturday, April 26
Education Session
2:30 – 4 p.m. CT | Room S402 – McCormick Place South
Session ED19 – GLP-1: From Diabetes to Weight Loss to Cancer
2:31 – 2:51 p.m. CT: Breaking the obesity-cancer link: Preclinical evidence for the anticancer effects of GLP-1Ras
Presenter: Stephen D. Hursting, PhD
Sunday, April 27
Clinical Trials Plenary
1 – 3 p.m. CT | Arie Crown Theater – McCormick Lakeside Center (Level 2)
CTPLO1 – Advances in Immunotherapy
1:15 – 1:25 PM CT Discussant: Robert L. Ferris, MD, PhD
Poster Session
2 – 5 p.m. CT
Presenter: Margarita M. Dzama, PhD
PO.ET06.04 – Molecular Classification of Tumors for Diagnostics, Prognostics, and Therapeutic Outcomes (Section 22)
493 / 5 – Cingulin plays a role in PDAC organoid polarity and subtype
Presenter: Mariaelena Nabors
494 / 6 – Identifying vulnerabilities in basal-like pancreatic adenocarcinoma (PDAC)
Presenter: Sandra Zarmer
Major Symposium
3 – 4:30 p.m. CT | Room S402 – McCormick Place South (Level 4)
DC15 – Patient Advocate Poster Symposium
Chair: Patricia Spears
Monday, April 28
Poster Session
9 a.m. – 12 p.m. CT
PO.MCB07.03 – Gene Regulation and Transcription Factors 3 (Section 11)
Presenter: Dalia Martinez-Marin, PhD
PO.ET09.01 – Kinase and Phosphatase Inhibitors 1 (Section 21)
Presenter: Glenn P. Boyles, MD
Presenter: Chelsey Vranes, MD
PO.BCS01.14 – Application of Bioinformatics to Cancer Biology (Section 44)
2394 / 12 – Survival and response modeling using diverse mouse mammary tumor models
Presenter: Matthew D. Sutcliffe
2 – 5 p.m. CT
PO.MCB06.01 – Epigenetic Mechanisms of Cancer Resistance and Progression (Section 10)
2740 / 8 – Mechanisms of phase-separation driven chromatin looping in acute myeloid leukemia
Presenter: Tooba Rashid
PO.ET03.02 – Novel Drug Resistance Mechanisms (Section 22)
Presenter: Attila Szenasi, MD, PhD
PO.CL06.08 – Immune Checkpoints (Section 28)
Presenter: Alessandro Porrello, PhD
PO.CL01.03 – Liquid Biopsy: Circulating Nucleic Acids 1 (Section 29)
Presenter: Shetal A. Patel, MD, PhD
PO.PR01.03 – The Role of Physical Activity, Diet, Microbiome, Obesity, and Energy Balance in the Cancer Continuum (Section 48)
Presenter: Michael Kebede, MPH
LBPO.CL01 – Late-Breaking Research: Clinical Research 1 (Section 53)
LB221 / 18 – Clinical significance of ALDH1L1 expression in hormone receptor positive breast cancer
Presenter: Amira A. Abdellatef, PhD, MS
Mini-Symposium
2:30 – 4:45 p.m. CT | Room S103 – McCormick Place South (Level 1)
MS.ET09.02 – Novel Antitumor Agents
3 – 3:25 p.m. CT 3786 – Combination of MTA-cooperative PRMT5 inhibitor BMS-986504 and KRAS inhibitors for the treatment of MTAP-deleted KRAS-mutant pancreatic cancer
Presenter: Kristina Drizyte-Miller, PhD
Forum
5 – 6:30 p.m. CT | Room E352 – McCormick Lakeside Center (Level 3)
5:40 – 6 p.m. CT Pancreatic cancer
Presenter: Jen Jen Yeh, MD
Tuesday, April 29
Poster Session
9 a.m. – 12 p.m.
PO.IM02.04 – Epigenetic Regulation of Tumor Immunity (Section 38)
4847 / 17 – Dishevelled 2: A key regulator of tumor immunity in breast cancer
Presenter: Geetha P. Boligala
LBPO.ET03 – Late-Breaking Research: Experimental and Molecular Therapeutics 3 (Section 52)
LB288 / 11 – Determination of the MYC- and TEAD-dependent transcriptome in pancreatic cancer
Presenter: Brandon L. Mouery, PhD
LBPO.PS01 – Late-Breaking Research: Population Sciences (Section 54)
LB334 / 9 – Associations between adherence to American Cancer Society physical activity guidelines and long-term quality of life among breast cancer survivors in the black women’s health study
Presenter: Natasha Renee Burse, DrPH, MS
Advances in Technologies
10:15 – 11:45 a.m. CT | Room S406 (Vista Ballroom) – McCormick Place South (Level 4)
AT01 – Reality check: AI in Drug Discovery
10:42 – 11:02 a.m. CT Reminiscing about the future of AI in drug discovery
Presenter: Alexander Tropsha, PhD
Advances in Organ Site Research
10:15 – 11:45 a.m. CT | Room S103 – McCormick Place South (Level 1)
Chair: Charles M. Perou, PhD
AOS02 – Updates from SABCS 2024
11:20 – 11:35 a.m. CT Paired DNA and RNA analysis of CALGB 40603 (Alliance) reveals insights into the molecular and prognostic landscape of stage II-III triple-negative breast cancer
Presenter: Brooke Felsheim
11:40 – 11:45 a.m. CT
Closing remarks: Charles M. Perou, PhD
Poster Session
2 – 5 p.m. CT
PO.MCB01.02 – S/G2/M phase (Section 13)
5408 / 3 – Unraveling c-MYC role in DNA replication origin licensing through non-canonical pathways
Presenter: Dalia Fleifel
PO.CL08.03 – Targeted Therapies and Combinations 3 (Section 34)
Presenter: Madison Jenner
LBPO.IM03 – Late-Breaking Research: Immunology 3 (Section 54)
LB388 / 10 – Innate immunity-independent roles of 2’3′-cGAMP in tumor metastasis control
Presenter: Pengda Liu, PhD
Forum
5 – 6:30 p.m. CT | Room S401 – McCormick Place South (Level 4)
FO04 – Unlocking the Power of PROs to Assess Tolerability in Cancer Clinical Trials
5:32 – 5:52 p.m. CT Chronic low-grade AEs and treatment discontinuation: Challenging assumptions about tolerability
Presenter: Lynne Wagner, PhD
Wednesday, April 30
Poster Session
9 a.m. – 12 p.m. CT
PO.ET09.15 – Novel Antitumor Agents 4 (Section 21)
6872 / 16 – Repurposing the DNA labeling agent EdU for glioblastoma treatment
Presenter: Humeyra Kaanoglu